OPTIMA

BIG 22-02

Share This Post

Optimal personalised treatment of early breast cancer using multi-parameter analysis

Optimal personalised treatment of early breast cancer using multi-parameter analysis

Aim: 315 patients in the whole clinical trial, from 55 study locations.

GIM,  GOIRC

55 study locations are involved in Spain and other EU countries.

Sponsor: GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)

Pharma partner: PUMA BIOTECHNOLOGY, INC

More To Explore

RIBOLARIS

RIBOLARIS BIG 21-02 Share This Post Neoadjuvant and adjuvant RIBOciclib + endocrine therapy for cLinicAlly high-RISk ER+/HER2-negative breast cancer What This is a study being

Read More

OPTIMA

OPTIMA BIG 22-02 Share This Post Optimal personalised treatment of early breast cancer using multi-parameter analysis What Optimal personalised treatment of early breast cancer using

Read More